347 related articles for article (PubMed ID: 33931939)
1. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
[TBL] [Abstract][Full Text] [Related]
2. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
[TBL] [Abstract][Full Text] [Related]
3. A pre-existing population of ZEB2
Francescangeli F; Contavalli P; De Angelis ML; Careccia S; Signore M; Haas TL; Salaris F; Baiocchi M; Boe A; Giuliani A; Tcheremenskaia O; Pagliuca A; Guardiola O; Minchiotti G; Colace L; Ciardi A; D'Andrea V; La Torre F; Medema J; De Maria R; Zeuner A
J Exp Clin Cancer Res; 2020 Jan; 39(1):2. PubMed ID: 31910865
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen.
Park SM; Choi SB; Lee YS; Lee IK
Asian J Surg; 2021 May; 44(5):715-722. PubMed ID: 33468383
[TBL] [Abstract][Full Text] [Related]
6. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
9. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Li S; Zhu L; Yao L; Xia L; Pan L
BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
[TBL] [Abstract][Full Text] [Related]
10. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
11. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
Paré L; Marcuello E; Altés A; del Río E; Sedano L; Salazar J; Cortés A; Barnadas A; Baiget M
Br J Cancer; 2008 Oct; 99(7):1050-5. PubMed ID: 18797464
[TBL] [Abstract][Full Text] [Related]
15. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
[TBL] [Abstract][Full Text] [Related]
16. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma.
Chang PM; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer Sci; 2009 Feb; 100(2):278-83. PubMed ID: 19068092
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
